Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan - Neurent Medical's rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues - NeurentMedical.com / Frost.com
Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan

 

PRTODAY - Newswire & PRZOOM/ - London, United Kingdom, 11/13/2018 - Neurent Medical's rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues - NeurentMedical.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the European rhinitis therapy market, Frost & Sullivan recognises Neurent Medical with the 2018 European New Product Innovation Award for developing a non-surgical, minimally invasive device that uses radio frequency (RF) to modulate a nerve group to offer relief from nasal obstruction and rhinorrhea. With the total annual avoidable expenditure on the European allergy market, not limited to rhinitis, amounting between $50 billion and $150 billion, even back in 2014, Neurent Medical's out-patient device can help customers achieve significant savings by using RF in a highly targeted manner.

The current clinical gold standard approaches to treating chronic ear, nose, and throat infections range from avoiding various environmental triggers, which provides only temporary relief, to invasive surgery, which often requires lengthy recovery periods. Medications such as antihistamines, decongestants, and topical or systemic corticosteroids have limited patient and physician acceptance because of side effects, such as drowsiness, bleeding, drying, and crusting. In more severe cases, surface cautery of enlarged turbinates is performed as an out-patient procedure; however, side effects include edema and crusting in the nose that can last three weeks or longer. In such a scenario, Neurent Medical's single-use device presents exceptional value as it can be used in office settings, and patients can resume normal activity almost immediately after implantation.

"Neurent Medical has based its rhinitis device on its extensive research on neuronal activity in the nasal cavity and the cellular makeup of the nasal mucosa. These guiding principles have enabled the product to stand out as a low-powered RF treatment that targets the autonomic supply to the nasal turbinates, positively impacting both allergic and non-allergic rhinitis," said Arjunvasun, Industry Analyst at Frost & Sullivan. "The device uses a microelectrode array that is designed to deliver targeted energy to interrupt the autonomic function within mucosal structures of the nasal cavities to reverse inflammatory cascade. The device incorporates an intelligent RF generator to maximize the energy delivery to the intended target, while minimizing collateral damage to the sub-mucosal tissues."

Additionally, the device offers substantial cost savings by eliminating patients' dependence on pharmacotherapies and by requiring only a single out-patient procedure.

"Although the application of RF to treat rhinitis has been evaluated through clinical studies, Neurent Medical has pioneered its application in treating inflammation caused by rhinitis," noted Arjunvasun. "Research conducted at the National University of Ireland, Galway supports the claim that Neurent Medical’s solution is truly a game-changing technology for allergy patients worldwide."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognises the product’s value-added features/benefits and the increased return on investment (ROI) it provides to customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Neurent Medical

Neurent Medical Ltd (neurentmedical.com) is a privately held, venture backed, Galway (Ireland) based medical device company in the Ear, Nose and Throat market. The company designs and develops products for treating inflammatory diseases of the nasal cavities. The initial product offering reduces the primary symptoms of rhinitis, congestion and rhinorrhoea.

About Frost & Sullivan

Frost & Sullivan (frost.com), the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+] [Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
Frost & Sullivan | Neurent Medical
Contact: Claudia Toscano - Frost.com 
210-477-8417 claudia.toscano[.]frost.com
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & SullivanAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From Frost & Sullivan / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib
Ipsen and 3BP Announce First Patient Dosed in Phase I/II study for First-in-Class Radionuclide (IPN01087)
EC Approves Ipsen’s Cabometyx® (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
Market Entrants Offering Digitized Mass Spectrometry Solutions Gain a Competitive Edge over Traditional Vendors Finds Frost & Sullivan
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
Medtech & Pharma Platform Annual Event Celebrates its 5th Anniversary in Basel
Ipsen to Present New Data from its Oncology Portfolio At The 2018 European Society for Medical Oncology (ESMO) Congress
Arla Foods Ingredients Acclaimed by Frost & Sullivan for its Osteopontin-enriched ingredient, Lacprodan® OPN-10
SCHOTT Teams Up with Smart Skin Technologies
STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  RightITnow, Inc.

Visit  NAKIVO, Inc.

Visit  BizJobs.com





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)